Farah Fawaz

Senior Vice President at Allogene Therapeutics

Farah Fawaz is a highly experienced professional in the biopharmaceutical industry, currently serving as Senior Vice President at Allogene Therapeutics since October 2018, with a focus on GxP Quality and Compliance and CMC Quality. Prior to this role, Fawaz held the position of Executive Director of Commercial QC at Intarcia Therapeutics, Inc., and spent nearly a decade at Bayer HealthCare in various roles, including Director of Quality Control and Analytical Chemistry. Fawaz began the career as a Senior Scientist at Berlex and previously worked as a Post-doctoral fellow at the University of California, San Francisco. Fawaz holds a Ph.D. in Cellular and Molecular Biology from the University of Michigan and a B.S. in Biology from the American University of Beirut.

Links

Previous companies


Org chart

No direct reports

Teams

This person is not in any teams


Offices

This person is not in any offices


Allogene Therapeutics

1 followers

Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.


Industries

Employees

201-500

Links